{"domain":"quantumbiopharma.com","status":"valid","tier":"listed","authority":47,"verified":false,"title":"www.quantumbiopharma.com","summary":"Quantum BioPharma (NASDAQ: QNTM) develops therapies for neurodegenerative and inflammatory disorders, including Lucid-MS for multiple sclerosis and unbuzzd.","country":null,"country_source":null,"publisher_country":null,"publisher_country_source":null,"hosting_country":null,"llms_txt":"https://www.quantumbiopharma.com/llms.txt","llms_full_txt":null,"last_checked":"2026-10-26T02:10:58.419Z","agent_terms":null,"categories":["healthcare","science-research"],"capabilities":[],"inferred_tags":["neurodegenerative therapies","lucid-ms","multiple sclerosis","clinical trials","unbuzzd"],"audience":"mixed","agent_uses":["read_docs","buy"],"language":"en","platform_generated":false,"agent_summary":"NASDAQ-listed biopharma (QNTM) developing Lucid-MS for multiple sclerosis and sells UNBUZZD functional beverage; includes clinical trial information.","llms_txt_cached":"https://agentwebmap.com/v1/domain/quantumbiopharma.com/llms.txt","agentic":"transactional","section_keys":["blog-posts","pages"],"section_partial":false,"section_indexed_at":"2026-10-26T02:11:01.041Z"}